

Valentín Cuervas-Mons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8658703/publications.pdf>

Version: 2024-02-01

158
papers

4,536
citations

109321

35
h-index

118850

62
g-index

172
all docs

172
docs citations

172
times ranked

4775
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The ReSpECT™ Study. American Journal of Transplantation, 2009, 9, 327-336.	4.7	250
2	Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology, 1986, 6, 922-927.	7.3	179
3	Randomized Trial of Fluconazole versus Nystatin for the Prophylaxis of Candida Infection following Liver Transplantation. Journal of Infectious Diseases, 1996, 174, 583-588.	4.0	163
4	Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study. American Journal of Transplantation, 2013, 13, 1734-1745.	4.7	158
5	OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1. Transplantation, 1998, 66, 1645-1650.	1.0	139
6	Adult liver transplantation: An analysis of the early causes of death in 40 consecutive cases. Hepatology, 1986, 6, 495-501.	7.3	136
7	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. Gastroenterology, 2021, 160, 1151-1163.e3.	1.3	130
8	Hepatitis C Recurrence After Liver Transplantation: Viral and Histologic Response to Full-Dose Peg-Interferon and Ribavirin. American Journal of Transplantation, 2006, 6, 2348-2355.	4.7	123
9	Validation and refinement of survival models for liver retransplantation. Hepatology, 2003, 38, 460-469.	7.3	114
10	Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology, 1990, 98, 134-140.	1.3	112
11	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplantation Reviews, 2018, 32, 36-57.	2.9	104
12	Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transplantation, 2008, 14, 799-805.	2.4	93
13	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplantation, 2006, 12, 1464-1472.	2.4	92
14	Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. Journal of Hepatology, 2014, 61, 1020-1028.	3.7	90
15	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. Journal of Hepatology, 2017, 66, 718-723.	3.7	90
16	Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplantation, 2002, 8, 123-131.	2.4	89
17	New concepts and best practices for management of pre- and post-transplantation cancer. Transplantation Reviews, 2012, 26, 261-279.	2.9	82
18	Donor Infection and Transmission to the Recipient of a Solid Allograft. American Journal of Transplantation, 2008, 8, 2420-2425.	4.7	74

#	ARTICLE	IF	CITATIONS
19	Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. <i>Regulatory Peptides</i> , 2007, 144, 50-55.	1.9	72
20	COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 724-725.	8.1	72
21	Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2008, 46, 20-27.	5.8	71
22	Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. <i>Transplantation Proceedings</i> , 2003, 35, 1907-1908.	0.6	70
23	Visceral Leishmaniasis (Kala-azar) in Solid Organ Transplantation: Report of Five Cases and Review. <i>Clinical Infectious Diseases</i> , 1999, 29, 918-921.	5.8	68
24	Does previous abdominal surgery alter the outcome of pediatric patients subjected to orthotopic liver transplantation?. <i>Gastroenterology</i> , 1986, 90, 853-857.	1.3	67
25	Mycophenolate Mofetil Can Be Used as Monotherapy Late After Liver Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 1650-1655.	4.7	65
26	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2014, 28, 84-91.	2.9	65
27	Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, 786-794.	6.0	60
28	Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. <i>Aids</i> , 2018, 32, 2347-2352.	2.2	55
29	Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. <i>Liver Transplantation</i> , 2017, 23, 498-509.	2.4	51
30	Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. <i>Antiviral Therapy</i> , 2017, 22, 307-312.	1.0	50
31	Incidence and outcome of De Novo malignancies after liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1275-1277.	0.6	44
32	Cardiovascular morbidity and obesity in adult liver transplant recipients. <i>Transplantation Proceedings</i> , 2003, 35, 1909-1910.	0.6	41
33	Biliary tract reconstruction after liver transplantation: With or without T-tube?. <i>Transplantation Proceedings</i> , 1997, 29, 564-565.	0.6	40
34	TIME-RELATED EFFICACY OF LIVER CELL ISOGRAFTS IN FULMINANT HEPATIC FAILURE. <i>Transplantation</i> , 1984, 38, 23-24.	1.0	36
35	Lipids and Lipoprotein Changes After Heart and Liver Transplantation in a Patient with Homozygous Familial Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 1988, 108, 204.	3.9	36
36	Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. <i>Liver Transplantation</i> , 2015, 21, 1056-1065.	2.4	35

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1874-1876.	0.6	34
38	Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post-Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 3960-3962.	0.6	34
39	A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. <i>Liver Transplantation</i> , 2009, 15, 1542-1552.	2.4	33
40	Serum IgE levels in liver cirrhosis.. Contrasting results in alcoholic and non-alcoholic patients. <i>Clinical and Experimental Allergy</i> , 1994, 24, 540-548.	2.9	32
41	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 2513-2522.	4.7	32
42	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	4.7	32
43	LIVER TRANSPLANT WITH ORGANS FROM ELDERLY DONORS: SPANISH EXPERIENCE WITH MORE THAN 300 LIVER DONORS OVER 70 YEARS OF AGE. <i>Transplantation</i> , 2002, 73, 1360.	1.0	31
44	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017, 31, 1653-1663.	2.2	30
45	Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. <i>World Journal of Hepatology</i> , 2019, 11, 50-64.	2.0	29
46	Plasma cell dyscrasia with polyneuritis and dermato-endocrine alterations. Report of a new case outside Japan. <i>Postgraduate Medical Journal</i> , 1980, 56, 427-430.	1.8	28
47	IN VIVO EFFICACY OF A BIOARTIFICIAL LIVER IN IMPROVING SPONTANEOUS RECOVERY FROM FULMINANT HEPATIC FAILURE: A CONTROLLED STUDY IN PIGS1. <i>Transplantation</i> , 2000, 69, 337-344.	1.0	28
48	Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2083-2088.	3.0	27
49	EVIDENCE THAT TEMPORARY COMPLETE OCCLUSION OF SPLENIC VESSELS PREVENTS MASSIVE EMBOLIZATION AND SUDDEN DEATH ASSOCIATED WITH INTRASPLENIC HEPATOCELLULAR TRANSPLANTATION. <i>Transplantation</i> , 1989, 47, 449-450.	1.0	26
50	Peginterferon and Ribavirin in Patients With HCV Cirrhosis After Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2207-2208.	0.6	26
51	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. <i>Transplant Infectious Disease</i> , 2017, 19, e12773.	1.7	26
52	Therapy of Intractable Pruritus With MARS. <i>Transplantation Proceedings</i> , 2005, 37, 1480-1481.	0.6	25
53	Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. <i>Transplant International</i> , 2006, 19, 641-648.	1.6	24
54	Liver Transplantation for Hepatic Trauma. <i>Transplantation</i> , 2016, 100, 2372-2381.	1.0	24

#	ARTICLE	IF	CITATIONS
55	Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 532-536.	5.0	22
56	De novo malignancies in liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 709-711.	0.6	21
57	Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860. <i>Transplantation</i> , 2012, 94, 275-280.	1.0	21
58	Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. <i>Transplant Infectious Disease</i> , 2015, 17, 488-492.	1.7	21
59	Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 1507-1508.	0.6	19
60	Five-Year Follow-up of a Trial Comparing Tacrolimus and Cyclosporine Microemulsion in Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1713-1715.	0.6	19
61	Toll-like Receptor 3 L412F Polymorphism May Protect Against Acute Graft Rejection in Adult Patients Undergoing Liver Transplantation for Hepatitis C-Related Cirrhosis. <i>Transplantation Proceedings</i> , 2011, 43, 2224-2226.	0.6	19
62	Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain. <i>Medicine (United States)</i> , 2021, 100, e25634.	1.0	19
63	De novo malignancies and liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1896-1897.	0.6	18
64	HIV type 2 epidemic in Spain. <i>Aids</i> , 2017, 31, 1353-1364.	2.2	18
65	Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. <i>Transplant International</i> , 1998, 11, S260-S266.	1.6	17
66	Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry. <i>International Journal of Infectious Diseases</i> , 2022, 116, 51-58.	3.3	17
67	Effectiveness of low-dose intramuscular Anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. <i>Transplantation Proceedings</i> , 2003, 35, 1850-1851.	0.6	16
68	Breakthrough Rhinocerebral Mucormycosis in a Liver Transplant Patient Receiving Caspofungin. <i>Transplantation Proceedings</i> , 2009, 41, 1972-1975.	0.6	16
69	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362.	3.0	16
70	Oral care planning and handling of immunosuppressed heart, liver, and kidney transplant patients. <i>Special Care in Dentistry</i> , 1996, 16, 242-246.	0.8	15
71	Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients. <i>Clinical Transplantation</i> , 2015, 29, 667-677.	1.6	15
72	Risk Factors for Clostridium Difficile Diarrhea in Patients With Solid Organ Transplantation. <i>Progress in Transplantation</i> , 2016, 26, 231-237.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. <i>Transplant International</i> , 1998, 11, S260-S266.	1.6	14
74	Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1511-1513.	0.6	13
75	Recurrence of primary biliary cirrhosis after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 721-722.	0.6	13
76	Hepatitis C Virus Recurrence After Liver Transplantation: Influence of Immunosuppressive Regimens on Viral Load and Liver Histology. <i>Transplantation Proceedings</i> , 2006, 38, 2499-2501.	0.6	13
77	Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hypertension. <i>Hepatology</i> , 1998, 27, 332-338.	7.3	12
78	Documento de consenso de indicaciones de trasplante hepático. <i>Gastroenterología Y Hepatología</i> , 2003, 26, 355-375.	0.5	12
79	Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 716-720.	0.3	12
80	Radiographic features of liver allograft rejection. <i>Gastrointestinal Radiology</i> , 1986, 11, 326-329.	0.4	11
81	Right Adrenal Metastases of Hepatocarcinoma After Liver Transplantation: Case Report and Literature Review. <i>Transplantation Proceedings</i> , 2009, 41, 1067-1069.	0.6	11
82	Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 715-717.	0.6	10
83	Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. <i>Transplantation Proceedings</i> , 2003, 35, 1830-1831.	0.6	10
84	Efficacy of Hepatocellular Carcinoma Locoregional Therapies on Patients Waiting for Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1484-1485.	0.6	10
85	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	3.9	10
86	Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 818-824.	2.0	10
87	Prevalence and progression of chronic kidney disease after a liver transplant: a prospective, real-life, observational, two-year multicenter study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 538-543.	0.3	10
88	Influence of Kupffer cell phagocytosis blockade on the production of ovalbumin-specific IgE and IgG1 antibodies in an experimental model. <i>Clinical and Experimental Allergy</i> , 1993, 23, 15-20.	2.9	9
89	Late orthotopic liver retransplant: indications and survival. <i>Transplantation Proceedings</i> , 1999, 31, 511-514.	0.6	9
90	Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. <i>Liver Transplantation</i> , 2022, 28, 1039-1050.	2.4	9

#	ARTICLE	IF	CITATIONS
91	Effectiveness of Pegylated Interferon and Ribavirin in Patients With Liver HCV Cirrhosis. <i>Transplantation Proceedings</i> , 2005, 37, 1482-1483.	0.6	8
92	Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by tollá€like receptor 3 polymorphism. <i>Clinical Transplantation</i> , 2016, 30, 810-818.	1.6	8
93	Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. <i>Clinical and Experimental Medicine</i> , 2017, 17, 217-223.	3.6	8
94	Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid. <i>International Journal of Infectious Diseases</i> , 2022, 116, 339-343.	3.3	8
95	Mast cell-mediated splanchnic cholestatic inflammation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 561-574.	1.5	7
96	Results of Liver Transplantation in Patients With Previous Portosystemic Shunts. <i>Transplantation Proceedings</i> , 2005, 37, 1491-1492.	0.6	6
97	CC Genotype at rs12979860 of IL28B Is Associated With Lower Risk of New-onset Diabetes After Transplantation in Adult Patients With Liver Transplantation for Hepatitis C Cirrhosis. <i>Transplantation Proceedings</i> , 2014, 46, 3114-3116.	0.6	6
98	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. <i>Transplant International</i> , 2017, 30, 1041-1050.	1.6	6
99	Impact of <i>ITPA</i> Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2017, 22, 571-575.	1.0	6
100	Effect of colistin on reduction of biliary flow induced by endotoxin of E. coli. <i>Digestive Diseases and Sciences</i> , 1982, 27, 875-879.	2.3	5
101	Late mortality in patients with liver transplantation: causes and risk factors. <i>Transplantation Proceedings</i> , 2003, 35, 707-708.	0.6	5
102	Prevalence of Hepatitis C Virus Genotypes in a Spanish Liver Transplant Unit. <i>Transplantation Proceedings</i> , 2005, 37, 1486-1487.	0.6	5
103	Adrenergic Response of Splanchnic Arteries from Cirrhotic Patients: Role of Nitric Oxide, Prostanoids, and Reactive Oxygen Species. <i>Experimental Biology and Medicine</i> , 2007, 232, 1360-1367.	2.4	5
104	Endothelium-dependent relaxation of isolated splanchnic arteries from cirrhotic patients: Role of reactive oxygen species. <i>Hepatology Research</i> , 2007, 37, 811-819.	3.4	5
105	TT Genotype of Transforming Growth Factor Beta1+869C/T Is Associated With the Development of Chronic Kidney Disease After Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3108-3110.	0.6	5
106	Activity and results of liver transplantation in Spain during 1984-2012. Analysis of the Spanish Liver Transplant Registry. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 337-347.	0.2	5
107	<i>TLR9</i>-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. <i>Biomarkers in Medicine</i> , 2019, 13, 995-1004.	1.4	5
108	Infection in Organ-Transplant Recipients. <i>New England Journal of Medicine</i> , 1998, 339, 1244-1246.	27.0	4

#	ARTICLE	IF	CITATIONS
109	Long-Term Survivors After Pediatric Liver Transplantation Are at Increased Risk for Development of Cardiovascular Disease Events: Analysis of 30 Cases. <i>Transplantation Proceedings</i> , 2014, 46, 3111-3113.	0.6	4
110	Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. <i>Transplantation Proceedings</i> , 1999, 31, 2461-2463.	0.6	3
111	V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. <i>Cirugía Española</i> , 2015, 93, 619-637.	0.2	3
112	Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. <i>Transplantation Proceedings</i> , 2016, 48, 3013-3016.	0.6	3
113	Rapid Changes in Cholesterol in Chronic Hepatitis C Patients Treated with Antivirals and Potential Impact on Cardiovascular Risk. <i>Journal of Hepatology</i> , 2016, 64, S790-S791.	3.7	3
114	Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. <i>Transplantation Proceedings</i> , 2016, 48, 2515-2518.	0.6	3
115	Benefits of hepatitis C cure with antivirals: why test and treat?. <i>Future Microbiology</i> , 2019, 14, 425-435.	2.0	3
116	Coronavirus Disease 2019 (COVID-19) in Solid Organ Transplant Recipients: A Case-Control Study. <i>Annals of Transplantation</i> , 2021, 26, e933152.	0.9	3
117	Medical workstation for the management of the transplantation unit of a hospital. , 0, , .		2
118	Influence of Infection by <i>Aspergillus</i> in Arterial Complications After Liver Transplantation: Evolution and Results in 670 Transplants. <i>Transplantation Proceedings</i> , 2011, 43, 751-752.	0.6	2
119	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. <i>Journal of Hepatology</i> , 2016, 64, S831.	3.7	2
120	Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. <i>Revista Española De Enfermedades Digestivas</i> , 2022, , .	0.3	2
121	Gadolinium chloride-induced Kupffer cell phagocytosis blockade promotes increased antibody (IgG1) response to orally administered ovalbumin in the rat. <i>International Hepatology Communications</i> , 1995, 3, 260-266.	0.7	1
122	Induction of peripheral chimerism in an allogenic model of small bowel transplantation with intrathymic inoculation of donor-derived cells. <i>Transplantation Proceedings</i> , 1997, 29, 1067-1069.	0.6	1
123	Hepatitis C Virus Sensitivity to Combined Antiviral Therapy in Liver Transplant Versus Immunocompetent Patients. <i>Transplantation Proceedings</i> , 2009, 41, 2195-2196.	0.6	1
124	Efficacy and Clinical Impact of Daclatasvir-Based Antiviral Therapy in Severe Recurrent Hepatitis C after Liver Transplantation. Results from a Multicenter Spanish Group. <i>Journal of Hepatology</i> , 2016, 64, S547.	3.7	1
125	Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience. <i>Journal of Hepatology</i> , 2016, 64, S794-S795.	3.7	1
126	Emergency department frequentation and unscheduled readmissions within the first year after liver transplantation, and their impact on survival. <i>Revista Española De Enfermedades Digestivas</i> , 2021, , .	0.3	1

#	ARTICLE	IF	CITATIONS
127	Autoimmune Extrahepatic Disorders in Patients With Autoimmune Liver Disease. Transplantation Proceedings, 2021, 53, 2695-2697.	0.6	1
128	OUTCOME OF RECURRENT AUTOINMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. Transplantation, 1998, 65, S25.	1.0	1
129	OUTCOME OF RECURRENT AUTOINMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. Transplantation, 1998, 65, 101.	1.0	1
130	Staphylococcus xylosus from a patient with cardiac and hepatic transplants. Clinical Microbiology Newsletter, 1988, 10, 47-48.	0.7	0
131	DOES PREVIOUS ABDOMINAL SURGERY ALTER THE OUTCOME OF PEDIATRIC PATIENTS SUBJECTED TO ORTHOTOPIC LIVER TRANSPLANTATION?. Journal of Pediatric Gastroenterology and Nutrition, 1988, 7, 474.	1.8	0
132	Utility of hepatocellular transplantation into spleen as a temporary liver support in cirrhotic dogs. Journal of Hepatology, 1990, 10, P8.	3.7	0
133	Role of the hepatic kupffer cells in the phagocytic splenic activity. Journal of Hepatology, 1991, 13, S126.	3.7	0
134	Hepatocellular carcinoma: adjuvant chemotherapy postliver transplant. European Journal of Cancer, 1999, 35, S141-S142.	2.8	0
135	PREVALENCE AND IMPACT ON LATE MORTALITY OF CARDIOVASCULAR RISK FACTORS IN AN ADULT LIVER TRANSPLANT POPULATION.. Transplantation, 2000, 69, S406.	1.0	0
136	BASILIXIMAB (SIMULECTÂ®) IS SAFE AND WELL TOLERATED IN ADULT LIVER TRANSPLANTATION AND PROVIDES A LOW RATE OF ACUTE REJECTION.. Transplantation, 2000, 69, S164.	1.0	0
137	THE DEPLETION OF Î³Î³+INTRAEPITHELIAL T CELLS FROM INTESTINAL ALLOGRAFTS AMELIORATES THEIR ACCEPTANCE IN MOUSE RECIPIENTS.. Transplantation, 2000, 69, S246.	1.0	0
138	DE NOVO HEPATITIS C DECREASES PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION.. Transplantation, 2000, 69, S314.	1.0	0
139	Trasplante hepÃ¡tico. Medicine, 2000, 8, 606-614.	0.0	0
140	Chronic renal failure after liver transplantation. Journal of Hepatology, 2002, 36, 191.	3.7	0
141	Recurrence of primary biliary cirrhosis after liver transplantation. Journal of Hepatology, 2002, 36, 194.	3.7	0
142	Effectiveness and security of mycophenolate mofetil as monotherapy in liver transplantation. Journal of Hepatology, 2003, 38, 45.	3.7	0
143	Influence of immunosuppressive therapy in the incidence of chronic renal failure after liver transplantation. Journal of Hepatology, 2003, 38, 45.	3.7	0
144	Preface. Transplantation Proceedings, 2009, 41, 2293.	0.6	0

#	ARTICLE	IF	CITATIONS
145	P908 EVEROLIMUS TREATMENT IN LIVER TRANSPLANTATION ACCORDING TO CLINICAL PRACTICE: A SPANISH MULTICENTRE COHORT. <i>Journal of Hepatology</i> , 2014, 60, S377-S378.	3.7	0
146	Spontaneous hepatitis C virus clearance in one HIV patient with chronic hepatitis C bearing IL28B-CC alleles and detectable plasma HIV-RNA. <i>Aids</i> , 2014, 28, 2169-2170.	2.2	0
147	P0040 : Long-term cardiovascular mortality after liver transplantation: Analysis of risk factors. <i>Journal of Hepatology</i> , 2015, 62, S306-S307.	3.7	0
148	Preface. <i>Transplantation Proceedings</i> , 2016, 48, 2855.	0.6	0
149	Fecal transplantation for the treatment of relapsing diarrhea associated with <i>Clostridium difficile</i> infection in a liver transplantation patient. <i>Medicina Clínica (English Edition)</i> , 2016, 146, e3-e4.	0.2	0
150	Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Genotype 1, after Liver Transplantation: Efficacy and Safety. <i>Journal of Hepatology</i> , 2016, 64, S538-S539.	3.7	0
151	Results of Radiofrequency Ablation in a Cohort of Cirrhotic Patients at Liver Transplantation. <i>Journal of Hepatology</i> , 2016, 64, S698.	3.7	0
152	Preface. <i>Transplantation Proceedings</i> , 2017, 49, 749.	0.6	0
153	Preface. <i>Transplantation Proceedings</i> , 2019, 51, 249.	0.6	0
154	Infección bacteriana temprana en el paciente con trasplante hepático. <i>Gastroenterología Y Hepatología</i> , 2004, 27, 95-100.	0.5	0
155	Inmunosupresión en el trasplante hepático. , 2008, , 199-207.		0
156	Trasplante clínico de hepatocitos. , 2008, , 556-560.		0
157	INFLUENCE OF ANTIVIRAL THERAPY IN THE NATURAL HISTORY OF HEPATITIS B VIRUS RECURRENCE AFTER LIVER TRANSPLANTATION: RETROSPECTIVE STUDY OF 14 CASES. <i>Transplantation</i> , 1999, 67, S201.	1.0	0
158	Risk Factors for <i>Clostridioides Difficile</i> Diarrhea In Solid Organ Transplantation Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 2826-2832.	0.6	0